Orgenesis has entered into an agreement with the John Hopkins University under which the institue will make use of Orgenesis’ point-of-care (Pocare) platform to devlop and supply a wide range of cell and gene therapies and technologies.
The Pocare platform provides cell and gene therapy solutions in a cost effective, high quality and scalable manner, using closed systems at the point of care.
(Source: Deposit Photos)
Maryland/USA – Orgenesis, a provider of point-of-care cell and gene therapy development, processing and treatment solutions (Pocare), has recently announced that it has entered into a collaboration agreement with the John Hopkins University (JHU). Under the terms of the agreement, JHU will utilise Orgenesis’ Point-of-Care (Pocare) platform to develop and supply a variety of cell and gene therapies and technologies, including cell-based immunotherapy technologies.
Vered Caplan, CEO of Orgenesis, stated, “JHU has unparalleled capabilities in the cell and gene therapy sector. Our Pocare platform is designed to provide unique cell and gene therapy solutions in a cost effective, high quality and scalable manner, using closed systems and other advanced cell processing technologies at the point of care. We look forward to utilising our Pocare platform to support JHU’s growing development and processing needs in order to advance and accelerate cell and gene based clinical therapeutic research. We believe this collaboration with JHU, a clear leader in the field of cell and gene therapy, further validates the significant value proposition of our Pocare platform. Moreover, this is the third major agreement signed by an international institution in recent months to utilise Orgenesis’ Pocare solutions.”
Unfold for details of your consent
Stand vom 23.03.2021
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.